Pharmaceutical Investing TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer 10 December
Pharmaceutical Investing Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma 09 December
